Will the FDA approve AstraZeneca's new cancer drug for any indication…

Market overview

An FDA advisory panel voted against AstraZeneca's new cancer drug. While not binding, panel rejections often precede a full FDA rejection, but the company may pursue other indications or provide more data.

Science prediction market

Implied probability (Yes)

25%

Closes

2029-07-30

More Science markets

• Climate Policy breaks new record this year? — 72% Yes
• Carbon Nanotubes breaks new record this year? — 37% Yes
• Will CRISPR dominate headlines in the next 6-10 months? — 59% Yes
• Major Fusion Energy development by June 2027? — 24% Yes
• Will the CDC report over 500 confirmed US Cyclospora cases in 2024? — 45% Yes
• Will the UK record a temperature of 38.0°C or higher in June 2024? — 20% Yes
• Will a G20 nation announce a ban on new petrol/diesel car sales before 2035? — 42% Yes
• Will the total number of elephant deaths officially linked to this specific incident exceed 20 by 2024-10-01? — 0% Yes

Browse all Science markets →